What To Do With $3.4 Billion? Deals And Dividends Says BMS’ Andreotti
This article was originally published in The Pink Sheet Daily
Executive Summary
BMS plans to use the $3.4 billion it will receive shortly from AstraZeneca for selling its stake in their diabetes JV to fund a dividend increase, business development and possibly a share repurchasing program, Andreotti tells investors at the Goldman Sachs meeting.